Small Cap Discoveries

Covalon Technologies (TSX.V: COV) Update with Brent Ashton

Kovalon Technologies (TSX‑V: COV) held a Small Cap Discoveries conference call on March 11, 2026 to present its Q1 update and broader strategic outlook. CEO Brent Ashton highlighted the company’s solid financial foundation—$17 million in cash and zero debt—providing flexibility for growth initiatives, dividend payments, equipment upgrades, and potential acquisitions. The firm has achieved a dramatic financial turnaround, doubling revenue over the past three years while expanding gross margins and cutting operating expenses, resulting in a $10 million bottom‑line swing. However, Q1 revenue slipped in the mid‑teens, a timing issue Ashton said, with Q2 already showing stronger order flow that should restore growth momentum for fiscal 2026. Ashton emphasized Kovalon’s core focus on three large healthcare markets: IV therapy, chronic wound care, and surgical procedures. Their IV contamination‑prevention solutions, Valgard and Kovalear, deliver a “triple benefit” of better patient outcomes, lower supply costs, and improved nursing workflow. Prestigious institutions such as Mayo Clinic and Memorial Sloan Kettering have adopted these products, and the company estimates it currently serves less than 1 % of U.S. acute‑care hospitals, indicating significant upside. Looking ahead, Ashton believes Kovalon is at an inflection point, with growing market traction, strong margins, and heightened interest from larger healthcare players. Continued commercialization of existing consumables, strategic acquisitions, and deeper penetration into hospital networks could drive recurring revenue and create substantial shareholder value.